Compare · KLRA vs NVO
KLRA vs NVO
Side-by-side comparison of Kailera Therapeutics Inc. (KLRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 93.6x KLRA ($2.30B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for KLRA).
- NVO has more recent analyst coverage (25 ratings vs 6 for KLRA).
- Company
- Kailera Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $17.76+7.38%
- $48.65+3.65%
- Market cap
- $2.30B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 6
- 9
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KLRA
- SEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.
- SEC Form 10-Q filed by Kailera Therapeutics Inc.
- Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
- SEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.
- SEC Form 4 filed by Officer Tregoning Kathleen
- SEC Form 3 filed by new insider Tregoning Kathleen
- Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
- Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S